The effect of locoregional therapies in patients with advanced hepatocellular carcinoma treated with sorafenib

Umut Sarpel(Mount Sinai Medical Center), Edward Kim(Icahn School of Medicine at Mount Sinai), John Spivack(Icahn School of Medicine at Mount Sinai), Samantha N. Aycart(Mount Sinai Medical Center), Daniel M. Labow(Danbury Hospital), Robert E. Sweeney(Icahn School of Medicine at Mount Sinai), Marina Heskel(Icahn School of Medicine at Mount Sinai), Yaniv Berger(Icahn School of Medicine at Mount Sinai), Martin P. Edwards(Pfizer (United States))

HPB

March 17, 2016

10.1016/j.hpb.2016.02.007

Cited by 9

Related Papers

Innate Immune Landscape in Early Lung Adenocarcinoma by Paired Single-Cell Analyses

|Cell|2017|1.2k

Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)

|Journal of Medicinal Chemistry|2011|924

Discovery of (10 <i>R</i> )-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro- <i>2H</i> -8,4-(metheno)pyrazolo[4,3- <i>h</i> ][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations

|Journal of Medicinal Chemistry|2014|587

Using the Golden Triangle to optimize clearance and oral absorption

|Bioorganic & Medicinal Chemistry Letters|2009|382

Lipophilic Efficiency as an Important Metric in Drug Design

|Journal of Medicinal Chemistry|2018|340